Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma
George Mellgard(Memorial Sloan Kettering Cancer Center), Rajshekhar Chakraborty(Columbia University Irving Medical Center), Ghulam R. Mohyuddin(University of Utah), Suzanne Lentzsch(UPMC Hillman Cancer Center), Andrew Eisenberger, Molly M. Gilligan(Columbia University Irving Medical Center), Edward R. Scheffer Cliff(Brigham and Women's Hospital), Divaya Bhutani(Columbia University Irving Medical Center)
Cited by 12
Related Papers
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
|The Lancet Oncology|2021|266
A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19
|Journal of Clinical Investigation|2021|172
Donor glucose-6-phosphate dehydrogenase deficiency decreases blood quality for transfusion
|Journal of Clinical Investigation|2020|116